W
WAVEMAN · COMPANY
DRMA · Dermata Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

DRMA

Dermata Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001853816
ACTIVIST 13D☆ WATCH
INSIDER NET · 180D
-$13
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
9
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$13 over 180 days
-$13 over 90 days
more than 65% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
9 funds added or opened last quarter
below 86% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
1.3% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
below 70% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Kyri K. Van Hoose disclosed a 5%+ stake (9.0%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -78.7%
-78.7%12M
-81%-54%-26%+2%2025-092025-102025-122026-032026-052026-072026-09 2026-02-17 · Bedoya-Toro Munera Maria E bought $1.3K2026-06-16 · Scott Kathleen D. sold $132026-06-01 · Kyri K. Van Hoose filed a 5%+ stake (9.0%)
INSIDER BUYINSIDER SELL13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
The record shows a net $13 sold by insiders over 180 days, 9 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Dermata Therapeutics, Inc. insiders sold a net $13 of stock across 6 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Scott Kathleen D.
Director
SELL
2026-06-16
11.0
$13
Bedoya-Toro Munera Maria E
SVP, Regulatory Affairs
BUY
2026-02-17
1,000.0
$1.3K
PROEHL GERALD T
President, CEO and Chairman
BUY
2021-11-23
20,000.0
$48.0K
HALE DAVID F
Director
BUY
2021-08-17
35,714.0
-
PROEHL GERALD T
President, CEO and Chairman
BUY
2021-08-17
142,857.0
-
6 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
GEODE CAPITAL MANAGEMENT, LLC
20,203.0 sh
$26.1K
Welch & Forbes LLC
20,000.0 sh
$25.8K
STATE STREET CORP
18,747.0 sh
$24.2K
UBS Group AG
18,600.0 sh
$21.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLP
15,989.0 sh
$20.6K
5%+ owners
13D = intent to influence · 13G = passive
Kyri K. Van Hoose
ACTIVIST 13D · 2026-06-01
9.0%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Extended Market Index Fund
$25.8K POSITION · AS OF 2026-02-28
0.0%
Fidelity Series Total Market Index Fund
$1.3K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 1 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 3
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-7.8M$-12.5M$-8.0M$-9.7M
NET INCOME$-7.6M$-12.3M$-7.8M$-9.6M
EPS (DILUTED)-8.16-80.32-39.99
OPERATING CASH FLOW$-7.8M$-11.2M$-6.4M$-8.8M
CASH$7.5M$3.2M$6.2M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →